

15 August 2023

Company Announcements Office
Australian Securities Exchange

Breathe Life Sciences (BLS) to Launch AI-powered B2B Platform in Australia

Highlights

- **BLS has signed a joint venture with CanXChange for AI-Powered B2B therapeutic goods platform**
- **To launch Q4 2023 with focus on medicinal cannabis**
- **CanXChange is Europe's largest cannabis B2B online marketplace with €30m of transaction value to date**

Bioxyne Limited (ASX: BXN) (Bioxyne or Company) is pleased to announce that its wholly-owned subsidiary Breathe Life Sciences (BLS) and technology company [CanXChange](#) have executed a joint venture deal to launch an AI-powered B2B therapeutic goods platform in Australia.

The platform, expected to go live in Australia in Q4 2023, will target Australia's fast growing \$500 million medicinal cannabis market to facilitate wholesale trading between licensed buyers, sellers, cultivators, and accredited manufacturers in the country. The platform will also open international markets for Australian medicinal cannabis companies licensed to export.

CanXChange is the largest B2B cannabis platform in Europe with a strong reputation, market access, and technology. Headquartered in London, the company is building market infrastructure for the cannabis industry and specialises in providing digital exchange venues, payment, compliance, and data services.

CanXChange develops its own proprietary technologies and is at the forefront of AI research and development for its industry. With a global reach and with more than €30m of transactional volume to date, CanXChange has become Europe's largest cannabis B2B online marketplace.

Global cannabis market set to grow

The global cannabis market size is forecast to grow from US\$57.18 billion in 2023 to US\$444.34 billion by 2030, at a CAGR of 34.03% during the forecast period.

Sam Watson, Bioxyne CEO commented "We are excited to launch CanXChange Australia, operated and sponsored exclusively by our Australian licensed entity BLS Wholesalers. It's a phenomenal platform and tool, and we expect significant uptake in the market."

CanXChange CEO Alex Arkentis says "CanXchange has a significant track record in Europe working with Breathe Life Sciences, and this joint venture in Australia is a strong statement made by both companies to develop technological and operational efficiency standards for the Australian Medicinal cannabis industry, which has recently become the most coveted market for medicinal cannabis in the world. We look forward to working with BLS to develop this significant opportunity".

This announcement has been approved for release to the ASX by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited

sam@breathelifesciences.com

Guy Robertson
Chief Financial Officer
Bioxyne Limited

guy@bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an international Australian life sciences company headquartered in Sydney, and parent company of the Breathe Life Sciences Group. Bioxyne and wholly owned subsidiary [Breathe Life Sciences](#) manufacture and distribute consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. In Australia, Breathe Life Sciences holds controlled substance licenses to import, export, wholesale and manufacture Schedule 3,4 and 8 poisons (Medicinal cannabis), operating a wholesale distribution model as well as direct to patient supply of prescribed medications via telemedicine platform [BLS Clinics](#). Outside of Australia, the business has manufacturing and distribution centres in Japan, the UK, and Europe, and operates direct to consumer supply of its trademarked [Dr Watson](#)® brand.

For more information on Bioxyne, please visit <https://bioxyne.com>